A Phase 2 interventional study of Zilucoplan (RA101495) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 50th largest by enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2017, is one of 21 in phase 2, and was the 36th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 0–75
International PNH Interest Group · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 53 across the 54 interventional studies, 75 across the 13 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 68 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ra Pharmaceuticals, one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemoglobinuria, Paroxysmal with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT03520647National Heart, Lung, and Blood Institute (NHLBI)Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Drug: Zilucoplan (RA101495)
0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels.
Change-from-baseline through Week 12 in serum lactate dehydrogenase (LDH) levels
Time frame: Through Week 12 of the study
Change-from-baseline Bilirubin Values
Changes from baseline at each of the scheduled postbaseline time-points
Time frame: Through week 12
Change-from-baseline Total Hemoglobin Values
Changes from baseline at each of the scheduled postbaseline time-points
Time frame: Through week 12
Change-from-baseline Free Hemoglobin Values
Changes from baseline at each of the scheduled postbaseline time-points
Time frame: Through week 12
Change-from-baseline Haptoglobin Values
Changes from baseline at each of the scheduled postbaseline time-points
Time frame: Through week 12
Change-from-baseline Reticulocyte Values
Changes from baseline at each of the scheduled postbaseline time-points
Time frame: Through week 12
Change-from-baseline Hemoglobinuria Values
Changes from baseline at each of the scheduled postbaseline time-points Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
Time frame: Through week 12
| Milestone | Zilucoplan (RA101495) |
|---|---|
| Started | 3 |
| Completed | 3 |
| Not completed | 0 |
Change-from-baseline through Week 12 in serum lactate dehydrogenase (LDH) levels
| U/L | Zilucoplan (RA101495) |
|---|---|
| Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Levels. | 100.3 ± 128.0 |
Changes from baseline at each of the scheduled postbaseline time-points
| umol/L | Zilucoplan (RA101495) |
|---|---|
| Week 1 | -3.3 ± 5.1 |
| Week 2 | -4.7 ± 12.0 |
| Week 3 | -4.3 ± 7.5 |
| Week 4 | -0.3 ± 2.9 |
| Week 6 | -6.7 ± 17.5 |
| Week 8 | -2.3 ± 12.5 |
| Week 10 | -7.7 ± 14.8 |
| Week 12 | -2.0 ± 6.2 |
Changes from baseline at each of the scheduled postbaseline time-points
| g/L | Zilucoplan (RA101495) |
|---|---|
| Week 1 | 5.7 ± 4.2 |
| Week 2 | 3.3 ± 3.8 |
| Week 3 | 0.3 ± 4.0 |
| Week 4 | -0.3 ± 7.2 |
| Week 6 | 0.7 ± 5.8 |
| Week 8 | -3.3 ± 4.2 |
| Week 10 | 2.3 ± 3.1 |
| Week 12 | 0.3 ± 2.5 |
Changes from baseline at each of the scheduled postbaseline time-points
| mg/dL | Zilucoplan (RA101495) |
|---|---|
| Week 1 | -145.90 |
| Week 2 | -140.60 |
| Week 3 | -147.70 |
| Week 4 | -138.40 |
| Week 6 | -147.30 |
| Week 8 | -148.10 |
| Week 10 | -143.50 |
| Week 12 | -144.30 |
Changes from baseline at each of the scheduled postbaseline time-points
| g/L | Zilucoplan (RA101495) |
|---|---|
| Week 1 | 0.000 ± 0.000 |
| Week 2 | 0.000 ± 0.000 |
| Week 3 | 0.000 ± 0.000 |
| Week 4 | 0.133 ± 0.231 |
| Week 6 | 0.000 ± 0.000 |
| Week 8 | 0.000 ± 0.000 |
| Week 10 | 0.000 ± 0.000 |
| Week 12 | 0.000 ± 0.000 |
Changes from baseline at each of the scheduled postbaseline time-points
| 10^12 cells/L | Zilucoplan (RA101495) |
|---|---|
| Week 1 | -0.0190 ± 0.0382 |
| Week 2 | 0.0090 ± 0.0052 |
| Week 3 | 0.0430 ± 0.0327 |
| Week 4 | 0.0477 ± 0.0499 |
| Week 6 | 0.0310 ± 0.0157 |
| Week 8 | 0.0253 ± 0.0248 |
| Week 10 | 0.0350 ± 0.0350 |
| Week 12 | 0.0190 ± 0.0092 |
Changes from baseline at each of the scheduled postbaseline time-points Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
| score on a scale | Zilucoplan (RA101495) |
|---|---|
| Week 1 | 0.0 |
| Week 2 | 0.5 ± 0.7 |
| Week 3 | 0.5 ± 0.7 |
| Week 4 | 1.0 ± 1.4 |
| Week 6 | 0.5 ± 0.7 |
| Week 8 | 2.0 |
| Week 10 | 2.3 ± 2.5 |
| Week 12 | -0.3 ± 2.1 |
Collected over Through week 12 of the Study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zilucoplan (RA101495) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Zilucoplan (RA101495) |
|---|---|
| NauseaGastrointestinal disorders | 1/3 |
| Influenza like illnessGeneral disorders | 1/3 |
| Lipase increasedInvestigations | 1/3 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/3 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/3 |
| HeadacheNervous system disorders | 1/3 |
| HaemoglobinuriaRenal and urinary disorders | 1/3 |
| NephrolithiasisRenal and urinary disorders | 1/3 |
| Age, Categorical(Participants) | Zilucoplan (RA101495) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 3 |
| >=65 years | 0 |
| Age, Continuous(years) | Zilucoplan (RA101495) |
|---|---|
| Mean | 35.3 ± 16.3 |
| Sex: Female, Male(Participants) | Zilucoplan (RA101495) |
|---|---|
| Female | 1 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Zilucoplan (RA101495) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Zilucoplan (RA101495) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 1 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Zilucoplan (RA101495) |
|---|---|
| United States | 3 |
| Weight(kg) | Zilucoplan (RA101495) |
|---|---|
| Mean | 109.67 ± 13.97 |
| Height(cm) | Zilucoplan (RA101495) |
|---|---|
| Mean | 176.20 ± 7.60 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Mar 2018, 11 months.
Results were first posted in Feb 2020, 1 year 10 months after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 11 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan